drugset / Trial / NCT01626820

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults

NCT01626820

Phase 3 Completed 113 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza strains recommended for the 2012-2013 season.

Timeline

Start
2012-07-19
Primary completion
2012-08-10
Completion
2012-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluviral Vaccine Intramuscular

Indications